



Introduction to THCS project

Funded by the European Union under the Horizon Europe Framework Programme - Grant Agreement N°: 101095654. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.



Co-funded by the
European Union



- One of the Partnerships under Horizon Europe (Pillar 2 - Global Challenges & European Industrial Competitiveness)
- Total budget of appr. € 305 million and an EC Contribution of € 91 million (30% of the total budget)



- **64 partners**
- **23 Member States and HE Associated Countries**
- **9 regions**



Start: January 2023
Duration: 7 years

THCS Partnership




Co-funded by the
European Union

Funded by the European Union under the Horizon Europe Framework Programme - Grant Agreement N°: 101095654. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

THCS Vision and Objectives

**High-quality, fairly
accessible, sustainable,
efficient, resilient and
inclusive health and care
systems for all**



- **Increase funding opportunities and strengthen the research and innovation community**
- **Fill the knowledge gap**
- **Increase the ability to implement innovation**
- **Intensify cooperation among countries and beyond healthcare**
- **Increase stakeholders' involvement**

THCS Approach

Three main workstreams



Fill the knowledge gaps

Implementation and Transfer

Boosting Health and care systems

Problem and priorities definition

Learn from practices

learning what, why and how

People-centred health and care systems

Implementation and Transfer

Boost health systems

Pillars and Work Packages

PILLAR 1

Science & Innovation into
Policy and Practice

WP4 – Methodological and Assessment Framework

WP5– Bridging evidence to policy

PILLAR 2

Research and Innovation
funding

WP6 – Calls texts definition of R&I topics

WP7 – Joint Transnational Calls Secretariat

WP8 – Project Monitoring and Assessment of
Projects' results and impacts

PILLAR 3

Support transferability &
strengthening ecosystems

WP9 -Strengthening ecosystems

WP10 –Knowledge hub to support the
transferability of good practices

PILLAR 0

Programme management

WP1 – Governance and Annual Work Plan

WP2 – Coordination and Management

WP3 – Strategic relationship and Impact
maximisation



Co-funded by the
European Union

Funded by the European Union under the Horizon Europe Framework Programme - Grant Agreement N°: 101095654. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

For more information about THCS project

<https://www.thcspartnership.eu/>

**The webinar recording and presentations can be
accessed via THCS Knowledge Hub:**

<https://knowledgehub.thcspartnership.eu/login>



Re-STAGE




Integrative Decision Making in Rectal Cancer Care: Advanced Imaging, Predictive Models, and Patient-Centered Digital Tools

Andrada Ianuş

King's College London, UK

Algarve Biomedical Centre, Faro, Portugal

Champalimaud Foundation, Lisbon, Portugal



Champalimaud
Foundation




Institutul Oncologic
Prof. Dr. Ion Chiricuța



Motivation



Colorectal cancer is a major global health burden:

- Globally^{1,2}:
 - 3rd most diagnosed & 2nd leading cause of cancer deaths
 - ~1.9 million new case annually
 - Lifetime risk: ~1 in 23 for men, ~1 in 25 for women
- Incidence rising in younger adults³ (< 55 years)
 - 1 in 10 in 1995 vs 1 in 5 in 2019
 - Projected to further increase
- ~ 40 % case are rectal tumours
 - Unique diagnostic and treatment challenges
 - More aggressive in young adults, higher recurrence risk
 - Proximity to other pelvic organs – challenge for surgery and radiotherapy




Motivation



**Locally Advanced
Rectal Cancer**



**Neoadjuvant
therapy**



Restaging



Surgery



**Non-surgical
management**

- Watch and Wait is an established approach after neoadjuvant therapy in rectal cancer with undeniable advantages regarding QoL
- Pressure on adequate patient selection is building up, as evidence emerges on regrowth being associated with a higher rate of distant metastases
- MRI is essential for patient selection and to plan surgery in incomplete responders
- Response assessment on MRI has substantial variability of interpretation, and accuracy regarding response may be disappointing
- Uncertain time for patients, with many questions

Re-STAGE pillars

Basic research

- MRI biomarker development
- Tumour cells vs fibrosis vs muscle
- High resolution ex-vivo diffusion MRI
- Whole TME specimens
- 9.4T in Lisbon, 3T in Montpellier

Re-STAGE pillars

Basic research

- MRI biomarker development
- Tumour cells vs fibrosis vs muscle
- High resolution ex-vivo diffusion MRI
- Whole TME specimens
- 9.4T in Lisbon, 3T in Montpellier

Clinical translation

- Preclinical results - inform clinical protocols
- New MRI protocols added to the staging and restaging examination
- Evaluation of added value
- 1.5T and 3T , across all sites

Re-STAGE pillars

Basic research

- MRI biomarker development
- Tumour cells vs fibrosis vs muscle
- High resolution ex-vivo diffusion MRI
- Whole TME specimens
- 9.4T in Lisbon, 3T in Montpellier

Clinical translation

- Preclinical results - inform clinical protocols
- New MRI protocols added to the staging and restaging examination
- Evaluation of added value
- 1.5T and 3T , across all sites

Imaging repository

- Make the data available
- Enable future training of ML for outcome prediction

Re-STAGE pillars

Basic research

- MRI biomarker development
- Tumour cells vs fibrosis vs muscle
- High resolution ex-vivo diffusion MRI
- Whole TME specimens
- 9.4T in Lisbon, 3T in Montpellier

Clinical translation

- Preclinical results - inform clinical protocols
- New MRI protocols added to the staging and restaging examination
- Evaluation of added value
- 1.5T and 3T , across all sites

Imaging repository


- Make the data available
- Enable future training of ML for outcome prediction

Patient centred digital tools


- Mobile app to facilitate QoL questionnaires
- Provide information about the disease and treatment options
 - increase the knowledge, decrease anxiety

Where we are now: basic research


- **Ex-vivo high-resolution MRI of rectal cancer specimens and comparison with histology**
 - Resolution 0.5 mm³
- **Diffusion MRI vs standard contrasts**
 - Non invasive probe of tissue microstructure
 - E.g. cellularity, fibre orientation, etc



MRI images



Measure



Model




Tissue Microstructure

Where we are now: basic research


- **Diffusion tensor imaging:**
 - A simple model to describe diffusion in the tissue

Isotropic diffusion


Anisotropic diffusion




e.g. some tumours,
gray matter



Same in all directions



Easier along fibers





e.g. white matter, muscle

- DTI metrics:
 - Mean diffusivity (MD) – how fast the water molecule diffuse
 - Fractional anisotropy (FA) – how anisotropic the diffusion pattern is

Where we are now: basic research

- Correlation of MRI parameters with histology



Grossing

H&E

Averaged b3000

Color-coded FA

ROIs


Where we are now: basic research

- **Diffusion tensor imaging**


- Fractional anisotropy

Longitudinal Muscle Layer


Circular Muscle Layer



- **Sensitive to microscopic tumour pockets**




● specimen001 ■ specimen003 ◆ specimen004 ▲ specimen005




b3000 DWI

FA



H&E




Where we are now: clinical translation


- **Imaging protocol**

- A high-res Diffusion Tensor Imaging protocol
- Sequences with strong diffusion weighting
- Quantitative relaxometry

w/o diffusion weighting




w diffusion weighting




Preliminary diffusion tensor maps

- Resolution
- 1.4 x 1.4 x 4 mm


FA



Colour-coded FA



MD



Where we are now: digital tools

- **Website**

- Digital platform to support rectal cancer research and patient education: www.re-stage.eu
 - Basic information about the project
 - Consortium map and members
 - News and events

- Patient section with FAQ and Educational videos

- Designed based on major guideline recommendations
- Common patient concerns
- We worked together with patients



Where we are now: digital tools

- **Integrated AI chatbot – to be released soon**
 - Acts like a rectal cancer expert assistant
 - Powered by RAG + LLM (Retrieval Augmented Generation + Large Language Model)
 - Provides context-aware answers, trained on FAQ
 - Allows users to ask personalized questions (in any language)
 - Receive reliable, guideline-based answers

Answer from RAG + LLM

**Q** Can the biopsy come back benign even if cancer is really there?

**A** In rare cases, yes – a biopsy can miss hidden cancer. A negative report does not always mean “all clear”. A biopsy grabs only a tiny sample; if the malignant cells sit deeper in the wall the first sample may miss them. When the MRI or CT screams “cancer”, your multidisciplinary team can reach consensus based on unmistakable imaging results. The team will either:

1) repeat the biopsy (often with a bigger bite), or
2) move ahead with treatment as if it is cancer - because starting promptly is safer than waiting for the ‘perfect’ proof

**AI Assistant**
ⓘ AI models can make mistakes and are no substitute for medical advice





Sim, em casos raros, uma biópsia pode retornar negativa mesmo que o câncer esteja presente. Uma biópsia captura apenas uma pequena amostra do tecido, e se as células malignas estiverem mais profundas na parede, é possível que a amostra inicial não as detecte.

Se a ressonância magnética (MRI) ou tomografia computadorizada (CT) indicam sinais claros de câncer, sua equipe multidisciplinar pode decidir:

1. Repetir a biópsia (geralmente com uma amostra maior), ou
2. Avançar com o tratamento como se fosse câncer, pois começar o tratamento rapidamente é geralmente mais seguro do que esperar por uma prova "perfeita".

É importante discutir essas preocupações com seu médico para entender melhor sua situação específica.

- **Mobile application – industry partner in France**

- Improved and more reliable MR imaging in rectal cancer
- Better patient selection for Watch-and-Wait
- Faster decision to operate and more confident surgery planning for incomplete responders
- Better understanding of response variability to neoadjuvant therapy
- Happier, more informed patients

Thank you!



Champalimaud
Foundation



Introduction to MDR in AIS

Minimizing Door to Reperfusion Times in Drip and Ship Model for Patients with Acute Ischemic Stroke

SYNYO GmbH

Alexander Nikolov | Research Manager & Project Coordinator



PROGRAMME

European Partnership on Transforming Health and Care Systems (THCS):
European Union under the Horizon Europe Framework Programme –
Grant Agreement No. 101095654 (FFG grant agreement No. 50773503).

PROJECT DURATION

03/2024 to 03/2027 (36 month)

IDENTIFICATION CODE

FP-1127

COORDINATOR

AZIENDA OSPEDALIERO UNIVERSITARIA SENESE (AOUS)

PARTNERS

6 from 5 countries (Austria, Switzerland, Italy, Spain & Latvia)



Co-funded by
the European Union





CHALLENGES



Treatment Timeliness

Streamlining the workflow for secondarily transferred patients minimizes time to treatment, preserving brain function, reducing disability and long-term costs.



Complex Time-Dependent Stroke Networks Implementation

Optimizing coordination between primary stroke centers (PSCs), CSCs, and healthcare system. Addressing delays in recommended time targets for MT.



Feasibility and Implementation of Streamlined Pathways

Proposing a direct transfer pathway bypassing CSC's ED to reduce door to-groin(DTG)time and improve outcomes.



Variations in Healthcare Systems and Practices

Recognizing unique challenges due to variations among different healthcare systems, and considering evidence-based strategies adaptable to diverse settings.




Technological Advancements and Implementation

Acknowledging telemedicine potential in streamlining AIS care workflows.



Resource Allocation Optimization

Implementing distributed health and care models to optimize resource allocation in time-sensitive and critical settings such as stroke care.



OBJECTIVES



IMPROVE

the in-hospital workflow for LVO AIS patients to minimize treatment delays and optimize outcome



ASSESS

the efficacy and safety of the streamlined in-hospital workflow compared to the standard pathway



IDENTIFY

challenges and issues in stroke management and implementation of telemedicine



COMPARE

the outcomes and feasibility of the optimized workflow in different clinical settings and partner countries



EXPLORE


the potential application of streamlined pathways for other time-sensitive morbidities and improving services for all patients



MDR in AIS

EXPECTED PROJECT IMPACTS


Key information




Implementing an optimized pathway for LVO AIS patients



Minimizing treatment delays and optimizing outcomes




Advancing stroke management protocols



Exploring challenges and opportunities in telemedicine for stroke management



Addressing communication and coordination needs



Integrating telemedicine into existing workflows

Improving Stroke Management

Telemedicine Implementation

BROADER IMPACTS AND BENEFITS

Key information



Multicenter Collaboration

- Evaluating the optimized pathway across different clinical settings
- Sharing knowledge and improving stroke management on a broader scale



Economic Sustainability

- Assessing efficacy, safety and economic sustainability of the optimized workflow
- Providing evidence for cost reduction and resource optimization



Policy and Societal Impact

- Informing evidence-based policies and guidelines for stroke care
- Reducing disability and morbidity associated with AIS
- Enhancing the quality of life for stroke patients

SUBSCRIBE TO OUR NEWSLETTER

And we will keep you
up-to-date with our
latest project news!

MDR in AIS 



SCAN ME



Funded by the European Union



HOME NEWS EVENTS ABOUT CONSORTIUM MEDIA CONTACT

Minimizing Door to Reperfusion Times in Drip and Ship Model for Patients with Acute Ischemic Stroke





SCAN ME



Reducing Delays in Acute Ischemic Stroke Care

A multicenter retrospective evaluation of the drip-and-ship model across European stroke networks, examining treatment delays and outcomes in 572 patients from Italy, Spain, and Switzerland.



The Critical Challenge of Stroke Treatment

Time is Brain


Mechanical thrombectomy (MT) combined with intravenous thrombolysis is the gold standard for acute ischemic stroke with large vessel occlusion.

Geographic Barriers

MT is only available at Comprehensive Stroke Centers (CSC), which are fewer than Primary Stroke Centers (PSC).

Two Models

Drip-and-ship: treat at PSC then transfer. Mothership: direct transport to CSC.





Study Design & Network Comparison

572 Patients Analyzed

- AOUS Italy: 214 patients (37.4%)
- IBIMA Spain: 128 patients (22.4%)
- CHUV Switzerland: 230 patients (40.2%)

Network Coverage

- Italy: 11,562 km², 900K population
- Spain: 1.7M inhabitants, 5 PSCs
- Switzerland: 8,000 km², 1.5M population

Retrospective analysis conducted between 2018-2021 across three European stroke networks to evaluate treatment delays and outcomes.

Significant Timing Variations Revealed

67.7

AOUS Door-to-Groin

Minutes (Italy)

96.9

IBIMA Door-to-Groin

Minutes (Spain)

55.9

CHUV Door-to-Groin

Minutes (Switzerland)

Switzerland achieved fastest door-to-groin times by bypassing emergency department and transferring patients directly to angiography suite. Italy faced challenges with geographic distances and workflow protocols.



Key Findings & Future Directions



Substantial Inter-Institutional Variability

Significant differences in treatment approaches, timing metrics, and complication rates despite standardized protocols.




Workflow Optimization Opportunities

Direct angiography suite transfer, telemedicine integration, and AI-assisted imaging show promise for reducing delays.



MDR in AIS Project Impact

AI-assisted software introduced in 2024 across centers. Phase 2 will analyze whether telemedicine and AI optimization improves patient outcomes.





Discussion





Healthcare of the Future: Insights from Ageing Right Care(fully)

Dr. Jodi Sturge

Project lead, Ageing Right Care(fully)

Interaction Design, Faculty of Engineering Technology
University of Twente, Netherlands




Co-funded by
the European Union



Hospital or Home?

Housing Continuum and Hospital at Home




Source: Sturge, J., Nordin, S., Miedema, E., Dewit, I (2025, in press) *Designing for Relationality in Ageing in Place: A Systemic and Service Design Perspective on Healthcare and Housing Systems*. *Proceedings of Relating Systems Thinking and Design, RSD1*

Demographic shifts and demand for care at home

- Growing reliance on care at home, extended independent living
- Most older adults (80%) prefer to age in place and receive care at home rather than in a care facility (Eurofund 2017)
- Demand for care at home continues to grow due to ageing population and limited nursing capacity

Share of Older People Receiving Care at Home in Europe




Ageing Right Care(fully): Project Overview

- Transnational research project which aims to improve our understanding of the **care pathways between ageing in place and home hospitalization** of older adults.
- Special attention is paid to the role of different housing environments (**built, social, technological**) in supporting ageing in place and receiving hospital at home care.
- Comparing three different regions (**the Netherlands, Israel and Sweden**) to learn from each other and create actionable recommendations for policy and practice



Project
Protocol

Housing conditions for ageing in place and receiving health services at home




Source: Sturge et al. (2025). How to age right and care(fully) at home? A protocol for a multistage comparative study of ageing in place and hospital at home care across three countries. *BMJ Open*, 15(e096385).




Source: Sturge et al. (2025). How to age right and care(fully) at home? A protocol for a multistage comparative study of ageing in place and hospital at home care across three countries. *BMJ Open*, 15(e096385).

Bumps Along the Way




- Unequal funding amounts can impact capacity
- Diverse institutional ethic committee procedures

Bumps Along the Way



- Navigating different methods and adapting to new theoretical frameworks
- Differing standards of the scientific fields and dissemination means

Bumps Along the Way



- Policies, regulations are systemic and can be challenging to compare
- Healthcare terms and tacit knowledge difficult to explain/compare

Would you like to contribute?

Aim

- To better understand how H@H is organized and provided in different countries

Online Survey (max. 15 min)

- Targeting hospitals or organizations that are currently developing, testing, or implementing H@H care pathways
- Languages: Swedish, Dutch, English





Next Steps

- Develop a **composite indicator** for each country (built, social, technological) based on the SHARE database
- **Stakeholder interviews** on hospital at home for older adults
- **Co-create** a patient journey research method
- **Co-create patient journeys** with older people for touch and improvement points
- Develop a toolkit to **guide hospital at home policy and implementation** for older adults in the future

Follow up questions?

Dr. Jodi Sturge j.l.sturge@utwente.nl



<https://www.linkedin.com/in/jodi-sturge-phd-68660b62>

<https://www.arc-project.eu/>